Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, case-report, and clinical trial literature without a systematic review protocol
PubMed 41560340 · doi:10.1111/add.70319
What was done
The authors reviewed literature from observational studies, open-label trials, case reports, and limited randomized placebo-controlled trials assessing the therapeutic efficacy and cardiotoxic risks of ibogaine and its metabolite noribogaine for opioid and cocaine dependence.
What was found
No quantitative data or exact incidence rates are reported in the abstract. Qualitatively, ibogaine and noribogaine reduce craving and withdrawal symptoms, but carry a risk of QTc prolongation and potentially fatal ventricular arrhythmias (such as Torsades de Pointes), which can occur at therapeutic doses and in individuals without pre-existing cardiac conditions.
Why it matters
Despite anti-addictive potential, ibogaine's cardiac risks necessitate strict medical supervision, ECG monitoring, CYP2D6 genotyping, or the development of safer non-cardiotoxic analogues.
Limits
This is a narrative review without reported systematic meta-analytic methods or pooled effect sizes. Safety observations are largely derived from case reports and limited trials, and abstract details lack precise risk estimates.